-->

Tag: second-line HCC treatment

Home / second-line HCC treatment

Categories

Nivolumab with ipilimumab is approved by the USFDA for unresectable or metastatic hepatocellular carcinoma

On April 11, 2025, the Food and Drug Administration sanctioned nivolumab (Opdivo, Bristol Myers Squibb Company) in conjunction with ipilimumab (Yervoy, Bristol Myers Squibb Company) for the first trea...
second-line-hcc-treatment

We Are Online! Chat With Us!
Scan the code